The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease.

Curr Opin Pharmacol

Concord Clinical School, The University of Sydney, New South Wales, Australia; Department of Gastroenterology, Concord Repatriation General Hospital, New South Wales, Australia; Department of Gastroenterology, Macquarie University & Macquarie University Hospital, New South Wales, Australia. Electron

Published: December 2020


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose Of The Review: Faecal microbiota transplantation (FMT) has emerged as a potent form of therapeutic microbial manipulation. There is much interest in exploring its potential in conditions such as inflammatory bowel disease (IBD) where disturbances in the gastrointestinal microbiota play a crucial role in disease pathogenesis.

Recent Findings: There are 4 randomized controlled trials of FMT as induction therapy in ulcerative colitis, with meta-analyses suggesting significant benefit over placebo. Allied microbial studies have identified potential microbial and metabolic predictors of therapeutic efficacy and highlighted the importance of optimizing future donor and patient selection. Recent literature has evaluated the use of complementary microbial manipulation through pre-antibiotics to improve treatment efficacy. Studies have also assessed the durability of FMT response and its use in maintenance therapy of UC. While data on FMT are more limited in Crohn's disease and pouchitis, cohort and pilot randomized controlled data a now also emerging in these areas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538387PMC
http://dx.doi.org/10.1016/j.coph.2020.08.009DOI Listing

Publication Analysis

Top Keywords

faecal microbiota
8
microbiota transplantation
8
inflammatory bowel
8
bowel disease
8
microbial manipulation
8
randomized controlled
8
role faecal
4
transplantation treatment
4
treatment inflammatory
4
disease
4

Similar Publications

Background: A plant-focused, healthy dietary pattern, such as the Mediterranean diet enriched with dietary fiber, polyphenols, and polyunsaturated fats, is well known to positively influence the gut microbiota. Conversely, a processed diet high in saturated fats and sugars negatively impacts gut diversity, potentially leading to weight gain, insulin resistance, and chronic, low-grade inflammation. Despite this understanding, the mechanisms by which the Mediterranean diet impacts the gut microbiota and its associated health benefits remain unclear.

View Article and Find Full Text PDF

[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].

Bull Cancer

September 2025

Service d'hématologie, département d'oncologie, hôpitaux universitaire de Genève (HUG), faculté de médecine, université de Genève, Genève, Suisse. Electronic address:

Acute graft-versus-host disease (GVHDa) is one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT) patients. While the first-line consensus treatment has been based on systemic corticosteroid therapy for many years, ruxolitinib has recently been approved and has become the standard second-line treatment. Nevertheless, the effectiveness of ruxolitinib remains limited to 40 % of cortico-resistant patients, raising the crucial question of selecting a third-line treatment.

View Article and Find Full Text PDF

Background: Dietary fiber supports metabolic health via microbial fermentation, producing short-chain fatty acids (SCFAs). However, metabolic responses to fiber vary between individuals, potentially due to differences in gut microbiota composition. The Prevotella-to-Bacteroides (P/B) ratio has emerged as a potential biomarker for fiber responsiveness.

View Article and Find Full Text PDF

Insights into gut microbiota and metabolite profiles during in vitro fermentation of Volvaria volvacea polysaccharides: unraveling the central role of Bacteroides thetaiotaomicron.

Food Chem

September 2025

State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, Jiangsu 214122, China; School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China; International Joint Research Laboratory for Probiotics, Jiangnan University, Wuxi, Jiangsu 214122, China. Ele

Volvaria volvacea polysaccharides (VVP) possess diverse bioactivities with promising applications in biomedicine and functional foods. This study investigated the metabolic fate of VVP in human gut microbiota and uncovered the pivotal role of Bacteroides thetaiotaomicron using in vitro fecal fermentation models. VVP selectively promoted B.

View Article and Find Full Text PDF

Gut microbiota and metabolites related intra-patient variability of tacrolimus pharmacokinetics predicted adverse one-year outcomes following kidney transplantation.

Int Immunopharmacol

September 2025

Transplantation Center, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Key Laboratory of Translational Research in Transplantation Medicine of National Health Commission, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Clinical Resea

Kidney transplantation (KT) is an effective treatment for end-stage renal disease, with over 90 % of recipients requiring lifelong tacrolimus (Tac). However, The Tac pharmacokinetics exhibit high intra-patient variability (IPV), posing significant challenges. This study included 102 KT recipients at our center from October 2022 to December 2023.

View Article and Find Full Text PDF